Research analyst, medium-term horizon, biotech, small-cap

Weighing The Pros And Cons Of InVivo Therapeutics

On March 17, 2014, InVivo Therapeutics (NASDAQ:NVIV) reported financial results for the fourth quarter and full year ended December 31, 2013. The company did not report revenues during the fourth quarter or full year 2013. This was in line with expectations. Net loss in the fourth quarter totaled $5.7 million, driven by $3.7 million in R&D and $2.0 million in SG&A expense. For the full year, net loss totaled $38.8 million, driven by $10.5 million in R&D, $8.5 million in SG&A, and $18.9 million in non-cash accounting charges associated with the outstanding derivative liability. This liability was removed in June 2013, when the company successfully completed a $16.1 million warrant call.

From a cash burn standpoint, InVivo

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details